Neoleukin Therapeutics, Inc. NLTX
We take great care to ensure that the data presented and summarized in this overview for Neoleukin Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NLTX
View allLatest Institutional Activity in NLTX
Top Purchases
Top Sells
About NLTX
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Insider Transactions at NLTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2024
|
Stuart Cobb Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,391
+50.0%
|
-
|
|
Mar 13
2024
|
Christine Mikail Cvijic President and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
31,903
+37.65%
|
-
|
|
Oct 05
2023
|
Baker Bros. Advisors LP Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
592,650
+25.6%
|
-
|
|
Aug 17
2023
|
Baker Bros. Advisors LP Director |
BUY
Open market or private purchase
|
Indirect |
166,942
+1.32%
|
$0
$0.69 P/Share
|
|
Aug 16
2023
|
Baker Bros. Advisors LP Director |
BUY
Open market or private purchase
|
Indirect |
229,600
+1.82%
|
$0
$0.68 P/Share
|
|
Aug 15
2023
|
Baker Bros. Advisors LP Director |
BUY
Open market or private purchase
|
Indirect |
1,888,800
+12.18%
|
$0
$0.65 P/Share
|
|
Aug 11
2023
|
Sean Michael Smith Interim CFO, Prin Acct Off |
SELL
Open market or private sale
|
Direct |
1,323
-5.76%
|
$0
$0.62 P/Share
|
|
Aug 10
2023
|
Sean Michael Smith Interim CFO, Prin Acct Off |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+17.88%
|
-
|
|
Apr 03
2023
|
Priti Patel |
SELL
Open market or private sale
|
Direct |
3,769
-9.17%
|
$0
$0.69 P/Share
|
|
Mar 31
2023
|
Priti Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.58%
|
-
|
|
Feb 02
2023
|
Sean Michael Smith Interim CFO, Prin Acct Off |
SELL
Open market or private sale
|
Direct |
3,316
-17.2%
|
$0
$0.6 P/Share
|
|
Feb 02
2023
|
Priti Patel |
SELL
Open market or private sale
|
Direct |
14,380
-31.63%
|
$0
$0.6 P/Share
|
|
Feb 01
2023
|
Sean Michael Smith Interim CFO, Prin Acct Off |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+39.34%
|
-
|
|
Feb 01
2023
|
Priti Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+43.5%
|
-
|
|
Aug 10
2022
|
Sean Michael Smith Interim CFO, Prin Acct Off |
SELL
Open market or private sale
|
Direct |
1,655
-19.63%
|
$0
$0.99 P/Share
|
|
Aug 10
2022
|
Sean Michael Smith Interim CFO, Prin Acct Off |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+37.23%
|
-
|
|
May 02
2022
|
Priti Patel |
SELL
Open market or private sale
|
Direct |
5,538
-46.15%
|
$5,538
$1.22 P/Share
|
|
Apr 30
2022
|
Priti Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.45%
|
-
|
|
Aug 25
2021
|
Jonathan G Drachman President and CEO |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$300,000
$6.45 P/Share
|
|
Aug 24
2021
|
Jonathan G Drachman President and CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+4.08%
|
$600,000
$6.11 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 2.29M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 593K shares |
| Exercise of conversion of derivative security | 5K shares |
| Grant, award, or other acquisition | 52.3K shares |
| Open market or private sale | 1.32K shares |
|---|